February 11, 2020 / 11:33 PM / 14 days ago

BRIEF-Lilly And Incyte Announce Positive Top-Line Results From The North American Phase 3 Study Of Oral Selective JAK Inhibitor Baricitinib In Patients With Moderate- To Severe Atopic Dermatitis

Feb 11 (Reuters) - Incyte Corp:

* LILLY AND INCYTE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE NORTH AMERICAN PHASE 3 STUDY (BREEZE-AD5) OF ORAL SELECTIVE JAK INHIBITOR BARICITINIB IN PATIENTS WITH MODERATE- TO SEVERE ATOPIC DERMATITIS

* INCYTE CORP - STUDY MET PRIMARY ENDPOINT OF AT LEAST 75% IMPROVEMENT OF SKIN INFLAMMATION AND KEY SECONDARY ENDPOINTS

* INCYTE CORP - SAFETY PROFILE WAS CONSISTENT WITH KNOWN SAFETY FINDINGS OF BARICITINIB IN ATOPIC DERMATITIS

* INCYTE CORP - NO VENOUS THROMBOEMBOLIC EVENTS (VTES) OR DEATHS WERE REPORTED IN TRIAL. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below